-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network July 29th In the capital market, pharmaceutical bio-listed companies, especially enterprises with innovative properties become incense. As of July 28, a total of 160 companies, including 21 pharmaceutical and biological companies, have landed anumber in A-shares so far this year, according to
Tonghuashun.
since the opening of the board, a total of 29 pharmaceutical and biological companies to achieve the listing.
recently, the first A-H vaccine stock, is committed to the development of the new crown vaccine Kangsino bio is about to land on the board again attracted market attention.
according to reporters combing, Tyger Pharmaceuticals, Bai Oae, Zhao Yan new drugs and other A-share pharmaceutical bio-enterprises to speed up the pace of H-share listing.
the number of enterprises that want to be listed in the pharmaceutical and biological industries is increasing, among which the characteristics of A-H shares are more obvious.
pharmaceutical and bio-industry financing hot July 15, the Hong Kong Stock Exchange of Hong Kong and the United States NASDAQ dual-listed Baiji Shenzhou announced the completion of a registration of about $2.08 billion worth of direct issuance. Wang Xiaodong, founder of the
and chairman of the Scientific Advisory Board, said the company had raised more than $2 billion in just a few days, which was historic in itself and was the largest new equity raising ever issued by a biotech company in the world. Liang Heng, chief financial officer and chief strategy officer of
Baiji Shenzhou, said: "Baiji Shenzhou has always taken Chinese investors and the Chinese market very seriously, which is why we returned to Hong Kong two years ago to list on the Hong Kong Stock Exchange. "
We have been following up on the policies of A-shares and Co-shares, and are actively communicating and negotiating with relevant departments to maintain our interest in the domestic market and explore more possibilities in the future," Mr Leung said.
", in fact, the drug companies that have been listed in many places are not just one of Baiji Shenzhou.
comes after media reports that Reding Pharma, which is now listed on NASDAQ, is preparing to go back to Hong Kong, China.
in response to this, re-Ding Pharmaceuticals related people in response to the reporter said: "In recent years there have been rumors about re-Ding Pharmaceuticals to go to Hong Kong listing, we are not convenient to comment on rumors and speculation."
thank investors for their enthusiasm for the return of such a high-quality biopharmaceutical company.
" pharmaceutical companies plus code innovative drug field in the context of the review and approval of innovative drugs, domestic pharmaceutical companies have also added code innovation in the field.
behind the opening of diversified financing channels by pharmaceutical bio-enterprises, the pace of listing of new drugs has accelerated under the reform of the domestic drug review and approval system, and enterprises have increased their motivation to seize the dividends of reform and realize rapid development through financing.
,0G Securities research shows that since this year, including Jiangsu Hausson's Ometini, Baiji Shenzhou's Zambutini, Zhifei bio-recombinant tb fusion protein (EC), Sansheng Pharmaceutical's recombinant anti-HER2 human-derived monotomoinatis, Ganli Pharmaceutical's Mendong insulin and other approvals.
in addition, in the first half of the year, PD-1/PD-L1 was approved for a number of important indications, including Henri's CarelliZumab was approved for second-line liver cancer, non-scale non-small cell lung cancer and esophageal cancer.
Senrui Investment General Manager Lin Dian told reporters, from the target point of view, in addition to the existing PD-1, EGFR, HER2, CTLA-4, CD20, MDM2 and so on also began to become a hot spot;
the clinical number of anti-tumor drugs accounted for more than 50% of all new drugs clinical, is still the largest hot spot, and the number of rare disease niche drugs increased significantly and reached more than 10%, may become the next hot area;
Lin said some Chinese drug makers have a longer-term vision.
some enterprises for China's disease spectrum, tuberculosis, stroke, liver disease and other areas of new drug research and development, some enterprises extensive international cooperation in ME-BETTER drug research and development, the goal is to enter the global market, some enterprises focus on dual-anti-resistance, ADC drug platform research and development, and is expected to overtake in these sub-sectors.
.